Trials / Completed
CompletedNCT01836484
Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma
Diagnostic Accuracy of MRI, Diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 162 (actual)
- Sponsor
- Barts & The London NHS Trust · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective diagnostic performance study which compares three new imaging methods with the current standard imaging method for the diagnosis of metastatic lymph nodes.
Detailed description
The aim is to demonstrate whether leading edge molecular imaging technologies (FDG-PET/CT, DW-MRI and Fluoro-ethyl-choline (FEC) PET/CT) can identify lymph node metastases with sufficient accuracy to allow non-invasive lymph node staging in patients with endometrial and cervical carcinoma.
Conditions
- Surgically Staged Endometrial and Cervical Carcinoma
- Cervical Cancer: Invasive Disease, FIGO Stage 1B1 or Higher
- Endometrial Cancer
- Stage 1A With Myometrial Invasion or Any Higher Stage and Grade 3
- Stage 1A With Myometrial Invasion or Any Other Higher Stage and Serous Papillary or Clear Cell Sub-types
- Stage II Disease or Above and Any Histology Grade
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Diffusion-weighted MRI | |
| DIAGNOSTIC_TEST | Fluorodeoxyglucose-18-PET/CT | |
| DIAGNOSTIC_TEST | Fluoro-ethyl-coline-PET/CT |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2013-04-22
- Last updated
- 2020-02-13
Locations
7 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01836484. Inclusion in this directory is not an endorsement.